|
Market Cap | 702.58M | EPS (ttm) | 0.90 |
P/E | 9.28 | EPS this Y | -1.21% |
Forward P/E | 8.30 | EPS next Y | 12.33% |
PEG | 0.46 | EPS past 5Y | 40.40% |
P/S | 0.86 | EPS next 5Y | 20.00% |
P/B | 3.10 | EPS Q/Q | -92.47% |
Dividend | 7.76% | Sales Q/Q | -6.36% |
Insider Own | 3.10% | Inst Own | 94.02% |
Insider Trans | 0.00% | Inst Trans | -1.68% |
Short Float | 5.30% | Earnings | May 08/b |
Analyst Recom | 2.00 | Target Price | 12.67 |
Avg Volume | 1.12M | 52W Range | 8.30 - 17.85 |
|
|
|
Everi Holdings, Inc. engages in the provision of technology solutions to the casino, interactive, and gaming industry. It operates through the Games and Financial Technology Solutions (FinTech) segments. The Games segment focuses on leased gaming equipment, sales of gaming equipment, gaming systems, interactive solutions, and ancillary products and services. The FinTech segment provides access to cash at gaming facilities via ATM cash withdrawals, credit card cash access transactions and point of sale debit card cash access transactions, check-related services, fully integrated kiosks and maintenance services, compliance, audit and data software, casino credit data, and reporting services and other ancillary offerings. The company was founded on February 4, 2004 and is headquartered in Las Vegas, NV. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Lowenhar-Fisher Kate C. | EVP, Chief Legal Officer | Mar 22 '24 | Option Exercise | 0.00 | 16,666 | 0 | 50,011 | Mar 22 06:27 PM | JUDGE GEOFFREY P | Director | Nov 30 '23 | Option Exercise | 7.74 | 7,000 | 54,180 | 91,572 | Dec 01 04:03 PM | TAYLOR RANDY L | President & CEO | Aug 29 '23 | Option Exercise | 6.59 | 60,000 | 395,400 | 582,622 | Aug 30 06:17 PM | Rumbolz Michael D | Executive Chairman | Aug 29 '23 | Option Exercise | 6.59 | 50,000 | 329,500 | 1,108,320 | Aug 30 06:14 PM | TAYLOR RANDY L | President & CEO | Aug 29 '23 | Buy | 14.27 | 5,000 | 71,350 | 522,622 | Aug 30 06:17 PM |
|
|
|
|
Market Cap | 598.24M | EPS (ttm) | -1.13 |
P/E | - | EPS this Y | 12.54% |
Forward P/E | - | EPS next Y | 22.60% |
PEG | - | EPS past 5Y | 12.47% |
P/S | 4.31 | EPS next 5Y | 8.90% |
P/B | 3.50 | EPS Q/Q | 16.22% |
Dividend | - | Sales Q/Q | 21.61% |
Insider Own | 9.89% | Inst Own | 88.98% |
Insider Trans | -2.46% | Inst Trans | -0.55% |
Short Float | 7.01% | Earnings | May 06/a |
Analyst Recom | 1.00 | Target Price | 26.22 |
Avg Volume | 425.49K | 52W Range | 14.26 - 29.51 |
|
|
|
SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
RECUPERO ANTHONY J | President, Commercial Ops | Apr 03 '24 | Sale | 15.63 | 920 | 14,379 | 251,533 | Apr 04 07:59 PM | RECUPERO ANTHONY J | President, Commercial Ops | Apr 02 '24 | Sale | 15.50 | 3,307 | 51,272 | 252,453 | Apr 04 07:59 PM | Maheshwari Anshul | Chief Financial Officer | Apr 02 '24 | Sale | 15.45 | 2,425 | 37,474 | 205,516 | Apr 04 07:59 PM | RECUPERO ANTHONY J | President, Commercial Ops | Mar 13 '24 | Sale | 16.82 | 3,330 | 56,023 | 255,760 | Mar 14 05:46 PM | Nishimura Mika | Director | Mar 13 '24 | Sale | 16.22 | 2,500 | 40,550 | 19,350 | Mar 14 05:45 PM |
|
|
|
|
Market Cap | 419.38M | EPS (ttm) | -3.92 |
P/E | - | EPS this Y | 24.27% |
Forward P/E | - | EPS next Y | -15.86% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 0.63 | EPS Q/Q | -526.06% |
Dividend | - | Sales Q/Q | - |
Insider Own | 37.98% | Inst Own | 72.81% |
Insider Trans | -0.10% | Inst Trans | - |
Short Float | 12.79% | Earnings | Mar 28/a |
Analyst Recom | 1.40 | Target Price | 31.00 |
Avg Volume | 1.23M | 52W Range | 4.22 - 29.88 |
|
|
|
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Lin Shao-Lee | Chief Executive Officer | Apr 01 '24 | Sale | 6.63 | 9,961 | 66,024 | 1,577,374 | Apr 03 06:18 PM | Lin Shao-Lee | Chief Executive Officer | Feb 20 '24 | Sale | 7.60 | 15,701 | 119,403 | 1,587,335 | Feb 22 07:04 PM | Lin Shao-Lee | Chief Executive Officer | Jan 02 '24 | Sale | 7.41 | 10,691 | 79,188 | 1,603,036 | Jan 04 06:09 PM | Westlake BioPartners Fund II, | 10% Owner | May 09 '23 | Buy | 18.00 | 1,250,000 | 22,500,000 | 9,790,729 | May 11 09:16 PM | SEIDENBERG BETH C | Director | May 09 '23 | Buy | 18.00 | 1,250,000 | 22,500,000 | 9,790,729 | May 11 09:13 PM |
|
|
| |
|
Market Cap | 366.16M | EPS (ttm) | 0.18 |
P/E | 43.40 | EPS this Y | -32.44% |
Forward P/E | 4.09 | EPS next Y | 28.10% |
PEG | - | EPS past 5Y | -25.46% |
P/S | 0.15 | EPS next 5Y | - |
P/B | 0.61 | EPS Q/Q | -144.18% |
Dividend | 7.41% | Sales Q/Q | -5.25% |
Insider Own | 59.63% | Inst Own | 37.42% |
Insider Trans | 0.00% | Inst Trans | -1.96% |
Short Float | 16.76% | Earnings | May 08/a |
Analyst Recom | 2.43 | Target Price | 15.30 |
Avg Volume | 368.73K | 52W Range | 7.73 - 36.70 |
|
|
|
TTEC Holdings, Inc. is a digital global customer experience technology and services company. It focuses on the design, implementation, and delivery of transformative solutions for many brands. The firm operates through the following segments: TTEC Digital and TTEC Engage. The TTEC Digital segment provides design, build, and operate tech-enabled, insight-driven CX solutions. The TTEC Engage segment provides digitally-enabled customer care, acquisition, and fraud prevention services. The company was founded by Kenneth D. Tuchman in 1982 and is headquartered in Greenwood Village, CO. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Bourret Francois | CHIEF ACCOUNTING OFFICER | Apr 14 '24 | Option Exercise | 0.00 | 1,191 | 0 | 6,004 | Apr 16 04:44 PM | McLean Margaret B | GC & CRO | Apr 14 '24 | Option Exercise | 0.00 | 1,634 | 0 | 54,757 | Apr 16 04:51 PM | Bourret Francois | CHIEF ACCOUNTING OFFICER | Mar 17 '24 | Option Exercise | 0.00 | 2,718 | 0 | 5,832 | Mar 19 04:35 PM | Swanback Michelle R | PRESIDENT, CEO, TTEC ENGAGE | Mar 16 '24 | Option Exercise | 0.00 | 10,986 | 0 | 19,672 | Mar 19 04:31 PM | McLean Margaret B | GC & CRO | Mar 04 '24 | Option Exercise | 0.00 | 612 | 0 | 52,306 | Mar 06 04:39 PM |
|
|
|
|
Market Cap | 157.11M | EPS (ttm) | -0.08 |
P/E | - | EPS this Y | 50.00% |
Forward P/E | 12.48 | EPS next Y | 38.10% |
PEG | - | EPS past 5Y | 6.80% |
P/S | 1.40 | EPS next 5Y | 10.00% |
P/B | 2.15 | EPS Q/Q | -7.58% |
Dividend | - | Sales Q/Q | -0.96% |
Insider Own | 7.16% | Inst Own | 76.69% |
Insider Trans | 0.00% | Inst Trans | -2.27% |
Short Float | 1.67% | Earnings | Mar 07/b |
Analyst Recom | 1.00 | Target Price | 6.92 |
Avg Volume | 87.63K | 52W Range | 3.47 - 6.29 |
|
|
|
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Green James W | Chief Executive Officer | Aug 17 '23 | Buy | 4.38 | 25,000 | 109,500 | 2,862,679 | Aug 21 04:06 PM |
|
|
| |
|
Market Cap | 81.58B | EPS (ttm) | 0.36 |
P/E | 182.38 | EPS this Y | -43.71% |
Forward P/E | 9.08 | EPS next Y | 90.42% |
PEG | 33.92 | EPS past 5Y | 1.55% |
P/S | 2.98 | EPS next 5Y | 5.38% |
P/B | 4.67 | EPS Q/Q | -517.48% |
Dividend | 4.79% | Sales Q/Q | 5.66% |
Insider Own | 0.10% | Inst Own | 85.74% |
Insider Trans | -2.00% | Inst Trans | 0.85% |
Short Float | 1.70% | Earnings | Apr 25/a |
Analyst Recom | 2.22 | Target Price | 83.95 |
Avg Volume | 7.32M | 52W Range | 65.09 - 87.86 |
|
|
|
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
GILEAD SCIENCES, INC. | 10% Owner | Apr 02 '24 | Buy | 0.76 | 485,250 | 368,790 | 7,345,473 | Apr 03 06:50 PM | Parsey Merdad | Chief Medical Officer | Apr 01 '24 | Sale | 72.96 | 2,000 | 145,920 | 96,304 | Apr 02 06:38 PM | Parsey Merdad | Chief Medical Officer | Feb 29 '24 | Sale | 72.74 | 8,230 | 598,624 | 92,706 | Feb 29 06:35 PM | Parsey Merdad | Chief Medical Officer | Feb 28 '24 | Sale | 73.18 | 2,000 | 146,360 | 100,936 | Feb 29 06:35 PM | GILEAD SCIENCES, INC. | 10% Owner | Feb 12 '24 | Buy | 22.00 | 910,000 | 20,020,000 | 4,126,119 | Feb 13 05:48 PM |
|
|
|
|
Market Cap | 5.15B | EPS (ttm) | 7.22 |
P/E | 13.11 | EPS this Y | -19.81% |
Forward P/E | 6.70 | EPS next Y | 9.03% |
PEG | - | EPS past 5Y | - |
P/S | 0.27 | EPS next 5Y | -11.67% |
P/B | 2.21 | EPS Q/Q | -44.43% |
Dividend | 7.44% | Sales Q/Q | -3.44% |
Insider Own | 2.82% | Inst Own | 91.97% |
Insider Trans | 0.00% | Inst Trans | -2.98% |
Short Float | 13.39% | Earnings | Apr 24/a |
Analyst Recom | 2.89 | Target Price | 105.98 |
Avg Volume | 1.49M | 52W Range | 92.54 - 160.62 |
|
|
|
Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following segments: North America, Europe, Middle East and Africa (EMEA), Latin America, and Asia. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Fall River, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Perucchetti Alessandro | EVP, Whirlpool North America | Mar 01 '24 | Option Exercise | 0.00 | 658 | 0 | 6,425 | Mar 05 06:23 PM | Conley Christopher S | Vice President and Controller | Mar 01 '24 | Option Exercise | 0.00 | 968 | 0 | 3,591 | Mar 05 06:18 PM | Puente Juan Carlos | EVP & PRES. WHIRLPOOL LAR | Mar 01 '24 | Option Exercise | 0.00 | 1,004 | 0 | 19,336 | Mar 05 06:20 PM | Peters James W | EXEC VICE PRESIDENT AND CFO | Mar 01 '24 | Option Exercise | 0.00 | 9,606 | 0 | 50,370 | Mar 05 06:21 PM | Harter Ava | EVP & Chief Legal Officer | Mar 01 '24 | Option Exercise | 0.00 | 4,288 | 0 | 11,581 | Mar 05 06:30 PM |
|
|
| |
|
Market Cap | 145.09M | EPS (ttm) | -1.64 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -104.06% |
P/S | 0.29 | EPS next 5Y | 10.00% |
P/B | 0.46 | EPS Q/Q | -72.96% |
Dividend | - | Sales Q/Q | -5.45% |
Insider Own | 57.88% | Inst Own | 49.44% |
Insider Trans | 0.00% | Inst Trans | -7.92% |
Short Float | 2.84% | Earnings | Jan 09/a |
Analyst Recom | 1.00 | Target Price | 11.00 |
Avg Volume | 29.30K | 52W Range | 6.34 - 13.35 |
|
|
|
VOXX International Corp. engages in the manufacture and distribution of consumer electronic products. It operates through the following segments: Automotive Electronics, Consumer Electronics, and Biometrics. The Automotive Electronics segment offers products including entertainment devices, automotive security, remote start systems, mobile multimedia devices, and car-link smartphone telematics applications. The Consumer Electronics segment designs, manufactures, distributes, and markets products including home theater systems, high-end loudspeakers, outdoor speakers, business music systems, and cinema speakers. The Biometrics segment provides iris identification and biometric security related products. The company was founded by John J. Shalam in 1960 and is headquartered in Orlando, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Downing Steven R | Director | Jan 05 '24 | Buy | 10.00 | 1,568,750 | 15,687,500 | 3,312,558 | Jan 08 12:06 PM | Kahli Beat | President | Jan 05 '24 | Sale | 10.00 | 1,568,750 | 15,687,500 | 397,500 | Jan 09 09:27 AM | Downing Steven R | Director | Oct 06 '23 | Buy | 10.00 | 1,570,000 | 15,700,000 | 1,743,808 | Oct 10 04:09 PM | Kahli Beat | President | Oct 06 '23 | Sale | 10.00 | 1,568,750 | 15,687,500 | 598,750 | Oct 10 04:05 PM | Downing Steven R | Director | Aug 21 '23 | Buy | 8.65 | 5,000 | 43,250 | 173,808 | Aug 22 02:52 PM |
|
|
|
|
Market Cap | 354.35M | EPS (ttm) | -3.79 |
P/E | - | EPS this Y | 20.20% |
Forward P/E | - | EPS next Y | 57.85% |
PEG | - | EPS past 5Y | 0.57% |
P/S | 1.51 | EPS next 5Y | 11.60% |
P/B | - | EPS Q/Q | 66.08% |
Dividend | - | Sales Q/Q | 39.82% |
Insider Own | 8.63% | Inst Own | 75.24% |
Insider Trans | 0.01% | Inst Trans | 13.79% |
Short Float | 12.21% | Earnings | Feb 28/a |
Analyst Recom | 1.75 | Target Price | 14.91 |
Avg Volume | 1.81M | 52W Range | 3.23 - 37.98 |
|
|
|
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Jordan Erica | Chief Commercial Officer | Apr 16 '24 | Sale | 3.80 | 2,392 | 9,096 | 114,864 | Apr 17 04:34 PM | Schilke Tobin | CFO | Mar 18 '24 | Sale | 5.04 | 9,361 | 47,204 | 192,666 | Mar 19 06:44 PM | Sjuts Dustin S | President | Mar 18 '24 | Sale | 5.04 | 9,211 | 46,446 | 167,550 | Mar 19 06:45 PM | Moxie Dwight | CLO & GC | Mar 18 '24 | Sale | 5.04 | 8,125 | 40,971 | 137,815 | Mar 19 06:44 PM | Foley Mark J | CEO | Mar 06 '24 | Buy | 6.98 | 30,000 | 209,400 | 1,015,468 | Mar 08 04:33 PM |
|
|
|
|
Market Cap | 1.83B | EPS (ttm) | 2.83 |
P/E | 14.19 | EPS this Y | 1.37% |
Forward P/E | 8.06 | EPS next Y | 12.24% |
PEG | 1.33 | EPS past 5Y | 7.18% |
P/S | 1.39 | EPS next 5Y | 10.71% |
P/B | 2.40 | EPS Q/Q | -65.46% |
Dividend | - | Sales Q/Q | 6.93% |
Insider Own | 11.62% | Inst Own | 93.87% |
Insider Trans | 0.00% | Inst Trans | 2.19% |
Short Float | 1.53% | Earnings | Apr 25/b |
Analyst Recom | 1.33 | Target Price | 57.70 |
Avg Volume | 440.53K | 52W Range | 40.06 - 91.88 |
|
|
Apr-26-24 | Downgrade |
Deutsche Bank |
Buy → Hold |
$64 → $44 |
|
|
WNS (Holdings) Ltd. engages in the provision of business process management solutions. Its services include industry-specific offerings, customer interaction, finance and accounting, human resources, procurement, and research and analytics. It operates through the WNS Global BPM and WNS Auto Claims BPM segments. The WNS Global BPM is delivered out of its delivery centers in China Costa Rica, India, the Philippines, Poland, Romania, South Africa, Sri Lanka, the United Kingdom, and the U.S. The WNS Auto Claims BPM segment offers fault and non-fault repairs and legal services in relation to personal injury claims. The company was founded by Alan Stephen Dunning, David Charles Tibble and Neeraj Bhargava on February 18, 2002 and is headquartered in Mumbai, India. |
|
|